- Home
- JAZZ vs AXTA Comparison
JAZZ vs AXTA Comparison
Compare JAZZ & AXTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- AXTA
- Stock Information
- Founded
- JAZZ 2003
- AXTA 1910
- Country
- JAZZ Ireland
- AXTA United States
- Employees
- JAZZ N/A
- AXTA N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- AXTA Paints/Coatings
- Sector
- JAZZ Health Care
- AXTA Consumer Discretionary
- Exchange
- JAZZ Nasdaq
- AXTA Nasdaq
- Market Cap
- JAZZ 7.7B
- AXTA 6.7B
- IPO Year
- JAZZ 2007
- AXTA 2014
- Fundamental
- Price
- JAZZ $126.54
- AXTA $30.80
- Analyst Decision
- JAZZ Strong Buy
- AXTA Buy
- Analyst Count
- JAZZ 14
- AXTA 14
- Target Price
- JAZZ $178.93
- AXTA $39.00
- AVG Volume (30 Days)
- JAZZ 691.3K
- AXTA 2.1M
- Earning Date
- JAZZ 11-05-2025
- AXTA 10-29-2025
- Dividend Yield
- JAZZ N/A
- AXTA N/A
- EPS Growth
- JAZZ N/A
- AXTA 51.22
- EPS
- JAZZ N/A
- AXTA 2.04
- Revenue
- JAZZ $4,086,695,000.00
- AXTA $5,198,000,000.00
- Revenue This Year
- JAZZ $5.65
- AXTA $0.82
- Revenue Next Year
- JAZZ $5.79
- AXTA $2.97
- P/E Ratio
- JAZZ N/A
- AXTA $15.13
- Revenue Growth
- JAZZ 4.52
- AXTA N/A
- 52 Week Low
- JAZZ $95.49
- AXTA $27.58
- 52 Week High
- JAZZ $148.06
- AXTA $41.66
- Technical
- Relative Strength Index (RSI)
- JAZZ 56.53
- AXTA 49.34
- Support Level
- JAZZ $123.88
- AXTA $30.81
- Resistance Level
- JAZZ $129.50
- AXTA $31.81
- Average True Range (ATR)
- JAZZ 3.03
- AXTA 0.67
- MACD
- JAZZ -0.63
- AXTA -0.11
- Stochastic Oscillator
- JAZZ 29.24
- AXTA 12.40
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About AXTA Axalta Coating Systems Ltd.
Axalta Coating Systems Ltd is a manufacturer, marketer and distributor of high-performance coatings systems. It operates in two segments, The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial. The Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The company operates in the geographic areas of North America, EMEA countries, Asia-Pacific, and Latin America.